EASYMADE-TI
CG Bio Co., Ltd. · Decision date Apr 9, 2026
What did the FDA decide?
FDA records K252251 as a 510(k) premarket notification, with a decision dated Apr 9, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Neurology
- Decision date
- Apr 9, 2026
Regulatory record facts
- Identifier
- K252251
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- CG Bio Co., Ltd.
- Product code
- GXN
- Decision code
- SESE
- Decision date
- Apr 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Plate, Cranioplasty, Preformed, Non-Alterable.
- Applicant
- CG Bio Co., Ltd.
- Product code
- GXN
- FDA device class
- 2
FDA decision timeline
K252251 received
Application receipt date recorded by FDA.
K252251 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code GXN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cusmedi Co., Ltd. | 510(k) clearance | Nov 6, 2026 | FDA | |
| Longeviti Neuro Solutions | 510(k) clearance | Jun 25, 2026 | FDA | |
| The Surgeon General, Department of the Army (TSG-DA) | 510(k) clearance | Jun 18, 2026 | FDA | |
| Meticuly Co., Ltd. | 510(k) clearance | Jan 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
CG Bio Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Seoul
Sources and methodology
- Original FDA record: K252251
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


